EU: No SPCs For New Uses OF Existing Drugs
Ruling Reverses Court’s Landmark 'Neurim' Decision From 2012
Executive Summary
A judgment by the Court of Justice of the EU could offer new opportunities for generics firms but is bad news for innovators seeking supplementary protection certificates to protect new indications for their products.